{"id":66212,"date":"2026-05-25T21:43:47","date_gmt":"2026-05-25T13:43:47","guid":{"rendered":"https:\/\/flcube.com\/?p=66212"},"modified":"2026-05-25T21:43:48","modified_gmt":"2026-05-25T13:43:48","slug":"daiichi-sankyo-astrazeneca-secure-fda-approval-for-datroway-in-triple-negative-breast-cancer-after-phase-iii-tropion-breast02-success","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66212","title":{"rendered":"Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Success"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Daiichi Sankyo Company, Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/4568:TYO\">TYO: 4568<\/a>)<\/strong> and <strong>AstraZeneca PLC (<a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NASDAQ: AZN<\/a>)<\/strong> announced <strong>U.S. Food and Drug Administration (FDA) approval<\/strong> for their co-developed antibody drug conjugate (ADC) <strong>Datroway (datopotamab deruxtecan)<\/strong> as a treatment for <strong>adult patients with unresectable or metastatic triple-negative breast cancer (TNBC)<\/strong> who are not candidates for PD-1\/PD-L1 inhibitor therapy.<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-summary\" class=\"wp-block-heading\">Regulatory Approval Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Name<\/strong><\/td><td>Datroway (datopotamab deruxtecan)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Unresectable or metastatic TNBC (PD-1\/PD-L1 inhibitor ineligible)<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>U.S. FDA<\/td><\/tr><tr><td><strong>Approval Basis<\/strong><\/td><td>Phase III TROPION-Breast02 study<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>TROP2-targeting antibody drug conjugate (ADC)<\/td><\/tr><tr><td><strong>Partnership<\/strong><\/td><td>Daiichi Sankyo (Japan) \/ AstraZeneca (Global except Japan)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-pivotal-phase-iii-tropion-breast02-results\" class=\"wp-block-heading\">Pivotal Phase III TROPION-Breast02 Results<\/h2>\n\n\n\n<h3 id=\"h-overall-survival-primary-endpoint\" class=\"wp-block-heading\">Overall Survival (Primary Endpoint)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Median OS Benefit:<\/strong> 5.0 months improvement vs. chemotherapy<\/li>\n\n\n\n<li><strong>Hazard Ratio (HR):<\/strong> 0.79 (95% CI: 0.64\u20130.98; p = 0.0290)<\/li>\n\n\n\n<li><strong>Statistical Significance:<\/strong> Met primary endpoint with clinically meaningful benefit<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-progression-free-survival-key-secondary-endpoint\" class=\"wp-block-heading\">Progression-Free Survival (Key Secondary Endpoint)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Risk Reduction:<\/strong> 43% reduction in disease progression or death<\/li>\n\n\n\n<li><strong>Hazard Ratio (HR):<\/strong> 0.57 (95% CI: 0.47\u20130.69; p &lt; 0.0001)<\/li>\n\n\n\n<li><strong>Clinical Impact:<\/strong> Highly statistically significant improvement<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-treatment-response-rates\" class=\"wp-block-heading\">Treatment Response Rates<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Objective Response Rate (ORR):<\/strong> 64% with Datroway vs. 30% with chemotherapy<\/li>\n\n\n\n<li><strong>Response Magnitude:<\/strong> More than double the response rate compared to standard care<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-expanding-indication-portfolio\" class=\"wp-block-heading\">Expanding Indication Portfolio<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Datroway represents a cornerstone of the partners&#8217; ADC strategy, with an expanding global indication portfolio:<\/p>\n\n\n\n<h3 id=\"h-previous-approvals\" class=\"wp-block-heading\">Previous Approvals<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Japan (December 2024):<\/strong> HR-positive, HER2-negative unresectable\/recurrent breast cancer post-chemotherapy<\/li>\n\n\n\n<li><strong>US, EU, China (2025):<\/strong> Same HR+\/HER2- breast cancer indication as Japan approval<\/li>\n\n\n\n<li><strong>US (June 2025):<\/strong> Locally advanced\/metastatic EGFR-mutated NSCLC post-EGFR TKI and platinum chemotherapy<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-target-profile\" class=\"wp-block-heading\">Target Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Target:<\/strong> TROP2 (trophoblast cell-surface antigen 2)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Antibody drug conjugate delivering cytotoxic payload specifically to TROP2-expressing tumor cells<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> TROP2 is highly expressed in multiple solid tumors including TNBC, making it an attractive target for precision therapy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-implications-amp-commercial-outlook\" class=\"wp-block-heading\">Market Implications &amp; Commercial Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The TNBC approval significantly expands Datroway&#8217;s addressable patient population in the U.S., adding to its established presence in HR+\/HER2- breast cancer and NSCLC. With approximately <strong>40,000 new TNBC cases annually in the U.S.<\/strong>, and a substantial portion ineligible for immunotherapy, this approval creates a major commercial opportunity.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>5.0-month overall survival benefit<\/strong> positions Datroway as a new standard of care in this difficult-to-treat population, where treatment options have been limited and outcomes historically poor. The robust efficacy data across multiple endpoints\u2014survival, progression-free survival, and response rates\u2014demonstrates comprehensive clinical benefit.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Daiichi Sankyo and AstraZeneca&#8217;s ADC platform continues to validate its potential, with Datroway joining Enhertu in establishing the companies as leaders in next-generation targeted cancer therapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ due to risks including market competition, manufacturing supply, pricing negotiations, and evolving treatment guidelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Daiichi Sankyo Company, Limited (TYO: 4568) and AstraZeneca PLC (NASDAQ: AZN) announced U.S. Food and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":66214,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,130,16,194,871,15,978],"class_list":["post-66212","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-astrazeneca","tag-cancer","tag-daiichi-sankyo","tag-nasdaq-azn","tag-product-approvals","tag-tyo-4568"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Success - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Daiichi Sankyo Company, Limited (TYO: 4568) and AstraZeneca PLC (NASDAQ: AZN) announced U.S. Food and Drug Administration (FDA) approval for their co-developed antibody drug conjugate (ADC) Datroway (datopotamab deruxtecan) as a treatment for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1\/PD-L1 inhibitor therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66212\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Success\" \/>\n<meta property=\"og:description\" content=\"Daiichi Sankyo Company, Limited (TYO: 4568) and AstraZeneca PLC (NASDAQ: AZN) announced U.S. Food and Drug Administration (FDA) approval for their co-developed antibody drug conjugate (ADC) Datroway (datopotamab deruxtecan) as a treatment for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1\/PD-L1 inhibitor therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66212\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-25T13:43:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-25T13:43:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2502.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66212#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66212\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Success\",\"datePublished\":\"2026-05-25T13:43:47+00:00\",\"dateModified\":\"2026-05-25T13:43:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66212\"},\"wordCount\":454,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66212#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2502.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"AstraZeneca\",\"Cancer\",\"Daiichi Sankyo\",\"NASDAQ: AZN\",\"Product approvals\",\"TYO: 4568\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66212#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66212\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66212\",\"name\":\"Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Success - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66212#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66212#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2502.webp\",\"datePublished\":\"2026-05-25T13:43:47+00:00\",\"dateModified\":\"2026-05-25T13:43:48+00:00\",\"description\":\"Daiichi Sankyo Company, Limited (TYO: 4568) and AstraZeneca PLC (NASDAQ: AZN) announced U.S. Food and Drug Administration (FDA) approval for their co-developed antibody drug conjugate (ADC) Datroway (datopotamab deruxtecan) as a treatment for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1\\\/PD-L1 inhibitor therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66212#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66212\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66212#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2502.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2502.webp\",\"width\":1080,\"height\":608,\"caption\":\"Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Succes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66212#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Success\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Success - Insight, China&#039;s Pharmaceutical Industry","description":"Daiichi Sankyo Company, Limited (TYO: 4568) and AstraZeneca PLC (NASDAQ: AZN) announced U.S. Food and Drug Administration (FDA) approval for their co-developed antibody drug conjugate (ADC) Datroway (datopotamab deruxtecan) as a treatment for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1\/PD-L1 inhibitor therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66212","og_locale":"en_US","og_type":"article","og_title":"Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Success","og_description":"Daiichi Sankyo Company, Limited (TYO: 4568) and AstraZeneca PLC (NASDAQ: AZN) announced U.S. Food and Drug Administration (FDA) approval for their co-developed antibody drug conjugate (ADC) Datroway (datopotamab deruxtecan) as a treatment for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1\/PD-L1 inhibitor therapy.","og_url":"https:\/\/flcube.com\/?p=66212","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-25T13:43:47+00:00","article_modified_time":"2026-05-25T13:43:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2502.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66212#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66212"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Success","datePublished":"2026-05-25T13:43:47+00:00","dateModified":"2026-05-25T13:43:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66212"},"wordCount":454,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=66212#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2502.webp","keywords":["ADC \/ XDC","AstraZeneca","Cancer","Daiichi Sankyo","NASDAQ: AZN","Product approvals","TYO: 4568"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66212#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66212","url":"https:\/\/flcube.com\/?p=66212","name":"Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Success - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=66212#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=66212#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2502.webp","datePublished":"2026-05-25T13:43:47+00:00","dateModified":"2026-05-25T13:43:48+00:00","description":"Daiichi Sankyo Company, Limited (TYO: 4568) and AstraZeneca PLC (NASDAQ: AZN) announced U.S. Food and Drug Administration (FDA) approval for their co-developed antibody drug conjugate (ADC) Datroway (datopotamab deruxtecan) as a treatment for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1\/PD-L1 inhibitor therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66212#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66212"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=66212#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2502.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2502.webp","width":1080,"height":608,"caption":"Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Succes"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66212#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Success"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2502.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66212"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66212\/revisions"}],"predecessor-version":[{"id":66215,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66212\/revisions\/66215"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/66214"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}